Recommendations of national team of cardiologic and oncologic supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer;Rekomendacje krajowego zespołu nadzoru kardiologicznego i onkologicznego dotycza̧ce bezpieczeństwa kardiologicznego u chorych na raka piersi. Zapobieganie i postȩpowanie w powikłaniach sercowo-naczyniowych w raku piersi

Kardiologia Polska

Volumn 69, Issue 5, 2011, Pages 520-530

  Opolski, Grzegorz ^a   Krzakowski, Maciej ^b   Szmit, Sebastian ^a,c   Banach, Joanna ^d   Chudzik, Michał ^e   Cygankiewicz, Iwona ^e   Drozdz, Jarosław ^e   Filipiak, Krzysztof J ^a   Grabowski, Marcin ^a   Kaczmarek, Krzysztof ^e   Kochman, Janusz ^a   Lewek, Joanna ^e   Maciejewski, Marek ^e   Miśkiewicz, Zbigniew ^b   Niwińska, Anna ^b   Pieńkowski, Tadeusz ^b   Piestrzeniewicz, Katarzyna ^e   Sinkiewicz, Władysław ^d   Wranicz, Jerzy K ^e   Zawilska, Krystyna ^f  

^a WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MILITARY INSTITUTE OF MEDICINE   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f II Oddzial Chorob Wewnetrznych   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR DISEASE; HUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW;

EID: 79957652123     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Didkowska J, Wojciechowska U, Zatoński W. Nowotwory złośliwe w Polsce w 2007 roku. Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warszawa 2010.
2. National Comprehensive Cancer Network. Breast Cancer V2. 2010 (online: www.nccn.org).
3. Jassem J. Rak piersi. In: Krzakowski M et al. eds. Zalecenia postȩpowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2009. Via Medica, Gdańsk 2009.
4. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer, 2006; 6: 63.
5. Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation, 2004; 109: 3122-3131.
6. Lefrak E, Pitha J, Rosenheim S et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 1973; 32: 302-314.
7. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol, 2005; 23: 2900-2902. (Pubitemid 46224107)
8. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity Expert Opin. Drug Saf, 2006; 5: 791-809.
9. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep, 1978; 62: 873-879. (Pubitemid 8377881)
10. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med, 1991; 324: 808-815.
11. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep, 1978; 62: 887-891 (Pubitemid 8377883)
12. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med, 1995; 332: 1738-1743.
13. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol, 1993; 21: 477-479. (Pubitemid 23246302)
14. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol, 2005; 23: 8597-8605. (Pubitemid 46211501)
15. Minow RA, Gottlieb JA. Adriamycin cardiotoxicity. Ann Intern Med, 1975; 82: 855-856.
16. Rinehart JJ, Lewis RP, Balcerzak SP. Adriamycin cardiotoxicity in man. Ann Intern Med, 1974; 81: 475-478.
17. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol, 1997; 15: 1544-1552. (Pubitemid 27167391)
18. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol, 1975; 1: 63-76.
19. Kim YD, Lees DE, Lake CR et al. Hyperthermia potentiates doxorubicin- related cardiotoxic effects. JAMA, 1979; 241: 1816-1817. (Pubitemid 9225755)
20. Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol, 2007; 7: 67-71. (Pubitemid 47339869)
21. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991; 266: 1672-1677.
22. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of patients. Med Pediatr Oncol, 1995; 24: 352-361.
23. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med, 1995; 332: 1738-1743.
24. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol, 2006; 17: 1586-1591.
25. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol, 2001; 19: 191-196. (Pubitemid 32063496)
26. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. J Am Coll Cardiol, 2009; 53: 1343-1382.
27. Kasprzak JD, Hoffman P, Płońska E et al. Echokardiografia w praktyce klinicznej - Standardy Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego 2007. Kardiol Pol, 2007; 65: 1142-1162.
28. Barrett-Lee PJ, Dixon JM, Farell C et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol, 2009; 20: 816-827.
29. van Dalen EC, van den Brug M, Caron HN, Kremer LCM. Anthracycline- induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer, 2006; 42: 3199-3205. (Pubitemid 44854509)
30. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol, 2007; 25: 5490-5505. (Pubitemid 350232226)
31. th Ed. Chest, 2008; 133: 381S-453S.
32. Zawilska K, Brożek J, Jaeschke R et al. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej: aktualizacja 2009. Med Prakt, 2009; suppl.
33. Noble SI, Nelson A, Turner C et al. Acceptability of low molecular weight heparin prophylaxis for inpatients receiving palliative care: qualitative study. BMJ, 2006; 332: 577-580. (Pubitemid 44365756)
34. Patiar S. Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg, 2007; 94: 412-420. (Pubitemid 46624718)
35. Bergqvist D, Agnelli D, Cohen AT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 2002; 346: 975-980. (Pubitemid 34983247)
36. Wells PS, Anderson DR, Rodger M et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost, 2000; 83: 416-420. (Pubitemid 30148355)
37. Le Gal G, Righini M, Roy PM et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med, 2006; 144: 165-171. (Pubitemid 46780688)
38. Torbicki A, Perrier A, Konstantinides S et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J, 2008; 29: 2276-2315.
39. th Ed. Chest, 2008; 133: 454S-545S.
40. Ageno W, Manfredi E, Dentali F et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica, 2002; 87: 286-291. (Pubitemid 34212445)
41. Orzan F, Brusca A, Conte MR et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J, 1993; 69: 496-500. (Pubitemid 23212778)
42. Guidelines on the management of stable angina pectoris: executive summary. Recommendations of The Task Force of the European Society of Cardiology. Eur Heart J, 2006; 27: 1341-1381.
43. Brown ML, Schaff HV, Sundt TM. Conduit choice for coronary artery bypass grafting after mediastinal radiation. J Thoracic Cardiovasc Surg, 2007; 136: 1167-1171.
44. Nasso G, Canosa C, De Filippo CM et al. Thoracic radiation therapy and suitability of internal thoracic arteries for myocardial revascularization. Chest, 2005; 128: 1587-1592. (Pubitemid 41324451)
45. Gansera B, Schmidtler F, Angelis I et al. Quality of internal thoracic artery grafts after mediastinal irradiation. Ann Thorac Surg, 2007; 84: 1479-1484. (Pubitemid 47595312)
46. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1598-1660.
47. van der Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J, 2008; 29: 2909-2945.
48. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 2006; 114: 2474-2478.
49. Cardinale D, Colombo A, Lamantia G et al. Anthracycline induced cardiomyopathy - clinical revelance and response to pharmacologic therapy. J Am Coll Cardiol, 2010; 55: 213-220.